In 2014, Marshall et al. reported a lower frequency of known NPM1 and FLT3-ITD mutations in a South African AML cohort and suggested that race-specific mutations might contribute to AML pathogenesis and also to the lower frequency of detection of these mutations [14]. This evidence concerns the gene NPM1 and acute myeloid leukemia.